Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial

BACKGROUND: Immune checkpoint inhibitors (ICI) plus platinum-based chemotherapy has been recognized as a standard first-line therapy in non-small cell lung cancer (NSCLC); however, no prospective clinical trials of docetaxel (DTX) plus ramucirumab (RAM) following first-line ICI plus platinum-based c...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuzawa, Reiko, Morise, Masahiro, Ito, Kentaro, Hataji, Osamu, Takahashi, Kosuke, Koyama, Junji, Kuwatsuka, Yachiyo, Goto, Yasuhiro, Imaizumi, Kazuyoshi, Itani, Hidetoshi, Yamaguchi, Teppei, Zenke, Yoshitaka, Oki, Masahide, Ishii, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682525/
https://www.ncbi.nlm.nih.gov/pubmed/38034077
http://dx.doi.org/10.1016/j.eclinm.2023.102303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682525/
https://www.ncbi.nlm.nih.gov/pubmed/38034077
http://dx.doi.org/10.1016/j.eclinm.2023.102303

Ejemplares similares